

Try the modernized [ClinicalTrials.gov beta](#) website. Learn more about the [modernization effort](#).

 U.S. National Library of Medicine

ClinicalTrials.gov

[Find Studies](#) ▾

[About Studies](#) ▾

[Submit Studies](#) ▾

[Resources](#) ▾

[About Site](#) ▾

[PRS Login](#)

[Home](#) > [Search Results](#) > Study Record Detail

[Save this study](#)

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

⚠ Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT01029366

[Recruitment Status](#) : Completed

[First Posted](#) : December 10, 2009

[Results First Posted](#) : February 28, 2017

[Last Update Posted](#) : June 26, 2019

Sponsor:

University of Pennsylvania

Information provided by (Responsible Party):

University of Pennsylvania

[Study Details](#)

[Tabular View](#)

[Study Results](#)

[Disclaimer](#)

[? How to Read a Study Record](#)

Study Description

Go to ▾

Brief Summary:

This is a Pilot/Phase I, single arm, single center, open label study to determine the safety, efficacy and cellular kinetics of CART19 (CTL019) in chemotherapy resistant or refractory CD19+ leukemia and lymphoma subjects.

1) a Screening Phase, followed by 2) an Intervention/Treatment Phase consisting of apheresis, lymphodepleting chemotherapy (determined by the Investigator and based on subject's disease burden and histology, as well as on the prior chemotherapy history received), infusions of CTL019, tumor collection by bone marrow aspiration or lymph node biopsy (optional, depending on availability), and 3) a Follow-up Phase.

The suitability of subjects' T cells for CTL019 manufacturing was determined at study entry.

Subjects with adequate T cells were leukapheresed to obtain large numbers of peripheral blood mononuclear cells for CTL019 manufacturing. The T cells were purified from the peripheral blood mononuclear cells, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration. The number of subjects who had inadequate T cell collections, expansion or manufacturing compared to the number of subjects who had T cells successfully manufactured is a primary measure of feasibility of this study.

Unless contraindicated and medically not advisable based on previous chemotherapy, subjects were given conditioning chemotherapy prior to CTL019 infusion. The chemotherapy was completed 1 to 4 days before the planned infusion of the first dose of CTL019.

Up to 20 evaluable subjects with CD19+ leukemia or lymphoma were planned to be dosed with CTL019. A single dose of CTL019 (consisting of approximately 5×10^9 total cells, with a minimal acceptable dose for infusion of 1.5×10^7 CTL019 cells) was to be given to subjects as fractions (10%, 30% and 60% of the total dose) on Day 0, 1 and 2. A second 100% dose of CTL019 was initially permitted to be given on Day 11 to 14 to subjects, providing they had adequate tolerance to the first dose and sufficient CTL019 was manufactured.

Condition or disease <input type="checkbox"/>	Intervention/treatment <input type="checkbox"/>	Phase <input type="checkbox"/>
Hematopoietic/Lymphoid Cancer Adult Acute Lymphoblastic Leukemia in Remission B-cell Adult Acute Lymphoblastic Leukemia B-cell Chronic Lymphocytic Leukemia Prolymphocytic Leukemia Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Refractory Chronic Lymphocytic Leukemia Stage III Adult Diffuse Large Cell Lymphoma Stage III Chronic Lymphocytic Leukemia Stage III Grade 1 Follicular Lymphoma Stage III Grade 2 Follicular Lymphoma	Biological: CART-19	Phase 1

Stage III Mantle Cell Lymphoma		
Stage IV Adult Diffuse Large Cell Lymphoma		
Stage IV Chronic Lymphocytic Leukemia		
Stage IV Grade 1 Follicular Lymphoma		
Stage IV Grade 2 Follicular Lymphoma		
Stage IV Grade 3 Follicular Lymphoma		
Stage IV Mantle Cell Lymphoma		

Detailed Description:

Primary objectives:

1. To evaluate the safety and feasibility of a single target dose of 5 times 10^9 total cells, acceptable range of 1.5 times 10^7 to 5 times 10^9 total cells comprised of autologous CART-19 cells that express the TCR zeta and 4-1 BB costimulatory domain.

Secondary objectives:

1. Proof of mechanism: determine if 2nd generation CAR expressing 4-1BB costimulation domains have improved persistence in patients.
2. Proof of concept: determine the effects of CART-19 on CD19 expression in vivo.
3. Proof of bioactivity: Evaluate changes in systemic soluble immune factors in patients
4. Proof of bioactivity: Evaluate impact of CART19 treatment on tumor burden
5. Explore whether CART-19 cells retain anti-tumor activity in vivo.
6. Determine if host immunity develops against CART-19.
7. Characterize the relative subsets of CART-19 T cells (Tcm, Tem, and Treg).
8. Describe survival and response rates

Study Design

Go to ▼

Study Type : **Interventional (Clinical Trial)**

Actual Enrollment : 26 participants

Allocation: Non-Randomized

Intervention Model: Single Group Assignment

Masking: None (Open Label)

Primary Purpose: Treatment

Official Title: Pilot Study of Redirected Autologous T-cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma

Actual Study Start Date : March 17, 2010

Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

[MedlinePlus](#) related topics: [Leukemia](#) [Lymphoma](#)[Drug Information](#) available for: [Tisagenlecleucel-T](#)[Genetic and Rare Diseases Information Center](#) resources: [Lymphosarcoma](#)
[Acute Lymphoblastic Leukemia](#) [Lymphoblastic Lymphoma](#) [Diffuse Large B-Cell Lymphoma](#) [Chronic Lymphocytic Leukemia](#) [Mantle Cell Lymphoma](#)
[Follicular Lymphoma](#) [B-cell Lymphoma](#)[U.S. FDA Resources](#)

Arms and Interventions

Go to

Arm <input type="checkbox"/>	Intervention/treatment <input type="checkbox"/>
<p>Experimental: CART-19 CLL</p> <p>CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity. Minimum/maximum total dose: 1.5×10^7 / 5×10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).</p>	<p>Biological: CART-19</p> <p>Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.</p>
<p>Experimental: CART-19 ALL</p> <p>CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity. Minimum/maximum total dose: 1.5×10^7 / 5×10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).</p>	<p>Biological: CART-19</p> <p>Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.</p>

Primary Outcome Measures :

1. Number of Participants With Adverse Events [Time Frame: 5 years]

Secondary Outcome Measures :

1. Overall Response Summary [Time Frame: 5 years]

Efficacy assessments for ALL were performed based on bone marrow and blood morphologic criteria and physical examination findings. The definitions for response are primarily based on the standardized response criteria defined by National Comprehensive Cancer Network (NCCN) Guidelines (NCCN, 2013 v.1).

Efficacy assessments for CLL were based on lymphadenopathy, hepatomegaly, splenomegaly, bone marrow and blood morphologic and laboratory assessments. The response criteria are consistent with NCCN Guidelines Version 2.2012 CLL/SLL, which is based on the 2008 International Workshop Group on CLL (IWCLL) revisions of the original guidelines for evaluating disease response released in 1996 by the National Cancer Institute Working Group (NCI/WG).

Eligibility CriteriaGo to **Information from the National Library of Medicine**

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies](#).

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Criteria**Inclusion**

- Male and female subjects with CD19+ B cell malignancies in patients with no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.